



6-17-05

PATENT

Application S/N 10/607,035

Docket No. 202.2D4

Date: June 15, 2005

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL

Sir:

Transmitted herewith for filing is an information disclosure statement by Applicants.

For: **PHARMACEUTICAL COMPOSITIONS AND TREATMENT METHODS - 4**

Enclosed are:

- (X) Information disclosure statement listing 50 references.
- (X) Copies of 50 references cited in the IDS.
- (X) Certificate of mailing by express mail label No. EV 205130966 US.
- (X) Return postage prepaid postcard.

The Commissioner is hereby authorized to charge the \$180.00 fee under 37 C.F.R. § 1.17(p) and any other fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**. Small entity status has previously been claimed for this application.

Please use **Customer No. 26,551** for the correspondence address.

Date: June 15, 2005

Daryl D Muenchau

Daryl D. Muenchau
Registration No. 36,616
Attorney of Record
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-587-9333

06/20/2005 SSESHE1 00000007 501536 10607035
01 FC:1806 180.00 DA



Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY EXPRESS MAIL

Attorney Docket No. : 202.2D4

Applicant(s) : Clarence N. Ahlem, et al.

Application Serial No. : 10/607,035

For : Pharmaceutical Compositions and Treatment Methods - 4

Attorney : Daryl D. Muenchau, Registration No. 36,616

Express mail label No. : EV 205130966 US

Date of Deposit : June 15, 2005

I hereby certify that the accompanying:

transmittal form in duplicate, information disclosure statement for Serial No. 10/607,035 listing 50 references, copies of the 50 references cited in the IDS, return postage prepaid postcard


are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on June 15, 2005 and are addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda Mannon

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.2D4APPLICATION NO.
10/607,035INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Clarence N. Ahlem, et alFILING DATE
June 25, 2003GROUP
1616

(USE SEVERAL SHEETS IF NECESSARY)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	3,983,233	9-28-76	Brattsand et al.			
	4,383,992	5-17-83	Lipari			
	4,427,649	1-24-84	Dingle et al.			
	4,710,495	12-1-87	Bodor			
	4,898,694	02-06-90	Schwartz et al.			
	5,001,119	03-19-91	Schwartz et al.			
	5,028,631	07-02-91	Schwartz et al.			
	5,077,284	12-31-91	Loria et al			
	5,206,008	04-27-93	Loria			
	5,223,493	6-29-93	Boltralik			
	5,277,907	06-11-94	Loria			
	5,296,481	03-22-94	Partridge et al			
	5,424,463	06-13-95	Lardy et al.			
	5,461,042	10-24-95	Loria			
	5,506,223	04-09-96	Lardy et al.			
	5,585,371	12-17-96	Lardy			
	5,641,766	06-24-97	Lardy			
	5,686,438	11-11-97	Daynes et al			
	5,714,481	20-03-98	Schwartz et al.			
	5,811,418	09-22-98	Daynes et al			
	5,837,269	11-17-98	Daynes et al.			
	5,859,000	01-12-99	Dowell et al			
	5,912,240	06-15-99	Loria			
	6,187,767 B1	02-13-01	Araneo et al.			5-14-99
	6,197,762 B1	3-6-01	Garvey et al.			9-18-98
	6,667,299 B1	12-23-03	Ahlem et al			3-23-00
	6,794,374 B1	09-21-04	Weeks			11-27-00

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D4	APPLICATION NO. 10/607,035
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 25, 2003	GROUP 1616

U.S. PATENT APPLICATION PUBLICATIONS					
EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME AND PORTIONS OF DOCUMENT	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	US 2005/0075321 A1	Ahlem et al., first page and pages 102-107 (claims)			
	US 2004/0138187 A1	Ahlem et al., entire document			
	US 2004/0083231 A1	Ahlem et al., entire document			
	US 2004/0043973 A1	Ahlem et al., first page and pages 99-101 (claims)			
	US 2003/0060425 A1	Ahlem et al., entire document			

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 429 187 B1	05-01-94	Europe				
	EP 0 289 327 A1	11-02-88	Europe				
	EP 0 133 995 A2	08-08-84	Europe				
	DE 38 12 595 C2	10-27-88	Germany			X	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D4	APPLICATION NO. 10/607,035
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 25, 2003	GROUP 1616

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, ETC.)
	Araghi-Niknam et al., Cytokine Dysregulation and Increased Oxidation IS Prevented by Dehydroepiandrosterone in Mice Infected with Murine Leukemia Retrovirus, <i>Proc. Soc. Exp. Biol. Med.</i> 216(3):386-391 1997
	Araghi-Niknam et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS), <i>Immunology</i> 90:344-349 1997
	Bebo et al., Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, <i>J. Immunol.</i> 162:35-40 1999
	Henderson et al., Dehydroepiandrosterone and 16.alpha.-bromoepiandrosterone: Inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, <i>Carcinogenesis</i> , 2(7):683-686 1981
	Hernandez-Pando et al., The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, <i>Immunology</i> 95(2):234-241 1998
	Inserra et al., Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, <i>Proc. Soc. Exp. Biol. Med.</i> 218:76-82 1998
	Kang et al., Dehydroepiandrosterone and β -endorphin enhance IL-12 gene expression, <i>Chem. Abstracts</i> 126(9):99 abstract No. 113406a 1997
	Kang et al., Dehydroepiandrosterone and β -endorphin enhance IL-12 gene expression, <i>Taehan Misaengmulhak Hoechi (J. Korean Soc. Microbiology)</i> 31(4):399-404 1996 (translation from Korean)
	Manz et al., Methyl 17 β -Carboxyester Derivatives of Natural and Synthetic Glucocorticoids: Correlation Between Receptor Binding and Inhibition of in vitro Phytohaemagglutinin-Induced Lymphocyte Blastogenesis, <i>J. Clin. Chem. Clin. Biochem.</i> 21(2):69-75 1983
	Sigg et al., Methyl 3 α -acetoxyetien-(8:9 oder 8:14)-ate, Preliminary Communication, <i>Helvetica Chimica Acta</i> , 39(6):1507-1525 1956 (translation from German)
	Weisz et al., Selective reactions of some steroids with diethyl dicarbonate, <i>Archiv Pharmazie</i> 319:952-953 1986
	Xia, et al., Anti-AIDS agents. Part 36: 17-Carboxylated steroids as potential anti-HIV agents, <i>BIOORG Med. Chem</i> 7(9):1907-1911 1999
	Yang et al., Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA, <i>Aids Research and Human Retroviruses</i> 9(8):747-754 1993
	Zhang et al., Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, <i>Immunology</i> 96:291-297 1999